• TPA as a Causal Probe of ERK and Autophagy

  2026-10-01

  Discover how 12-O-tetradecanoyl phorbol-13-acetate (TPA) can function not only as an ERK/MAPK activator, but also as a causal perturbation tool for dissecting ERK/FoxO3a regulation and impaired autophagic flux. This guide translates recent mechanistic findings into practical assay and interpretation decisions.

• AG-490 for JAK2/STAT6 Macrophage Assays

  2026-09-30

  AG-490, also called Tyrphostin B42, provides a practical pharmacologic probe for testing whether exosome-driven macrophage polarization depends on JAK-linked signaling. This workflow emphasizes dose separation, pathway readouts, solvent controls, and interpretation limits in hepatocellular carcinoma models.

• APOE, Macrophage Polarization, and PTC Progression

  2026-09-30

  The reference study identifies APOE as a molecular link between papillary thyroid carcinoma cells, PI3K/Akt/NF-κB signaling, and M2-like macrophage polarization. Its integrated tissue, co-culture, and xenograft evidence suggests that APOE contributes to PTC progression and offers a framework for studying tumor–macrophage communication.

• Clozapine in Schizophrenia Circuit Research

  2026-09-29

  Clozapine provides a pharmacological benchmark for separating broad receptor effects from targeted prelimbic-cortex neuromodulation. This workflow connects ERK1/2 signaling activation, GABRE-focused assays, behavioral phenotyping, and hepatotoxicity studies while preserving clear experimental boundaries.

• SU 5402 Workflows for RTK and Neuron Studies

  2026-09-29

  SU 5402 supports quantitative interrogation of VEGFR2, FGFR, and PDGFR signaling in cancer models, while its use in human sensory-neuron systems is best positioned as an exploratory pathway perturbation. This guide connects phospho-signaling, cell-cycle, apoptosis, and HSV-1 latency readouts with practical controls and troubleshooting safeguards.

• Live-Dead Cell Staining Kit I: Calcein AM/PI

  2026-09-28

  The Live-Dead Cell Staining Kit I is a Calcein AM/PI staining kit for rapid fluorescence live/dead cell detection in mammalian cultures. Complementary esterase and membrane-integrity signals support cell viability and cytotoxicity workflows, but they do not independently identify every cell-death mechanism.

• Clozapine Workflows for Schizophrenia Research

  2026-09-28

  Use Clozapine to probe multi-receptor pharmacology, ERK1/2 responses, and liver liability in controlled research workflows. This guide pairs practical dose and timing strategies with a recent magnetic-stimulation study—while making clear that the study did not test Clozapine.

• Masitinib (AB1010): Practical KIT/PDGFR Workflow

  2026-09-27

  Masitinib (AB1010) is a DMSO-compatible tyrosine kinase inhibitor for studying KIT and PDGFRα/β signaling, including cancer, mast cell, and inflammatory model systems. It is not suitable for aqueous or ethanol-based workflows, and its effects in research assays should not be interpreted as evidence of clinical efficacy or target exclusivity.

• Mechanical Stress-Induced Autophagy and the Cytoskeleton

  2026-09-26

  The study finds that cytoskeletal microfilaments are required for changes in autophagosome number after compressive mechanical stress, while microtubules make a secondary contribution. Its combination of mechanical stimulation, cytoskeletal perturbation, fluorescence imaging, and immunoblotting offers a framework for investigating how cells translate physical forces into autophagy responses, while leaving questions about autophagic flux and the underlying signaling steps open.

• tFUS Limits Post-Stroke NLRP3 Neuroinflammation

  2026-09-25

  In a rat ischemic-stroke model and complementary microglial experiments, transcranial focused ultrasound stimulation (tFUS) improved neurological outcomes while reducing NLRP3 inflammasome activation. The study connects these effects to a Nespas/miR-383-3p/SHP2 regulatory pathway, providing a mechanistic basis for further testing of non-invasive neuromodulation in post-stroke neuroinflammation.

• AG-490 in Exosomal JAK2/STAT6 Research

  2026-09-25

  Use AG-490 to test whether exosomal SNORD52-associated macrophage changes depend on kinase signaling—not simply to label a pathway as active. This workflow pairs dose-aware inhibitor controls with exosome, phosphorylation, and polarization readouts for more interpretable hepatocellular carcinoma research.

• Catalpol Workflows for Translational Research

  2026-09-24

  Catalpol offers a practical way to test multi-pathway biology across neuroprotection, bone, stroke, and liver-fibrosis models. This guide turns the available evidence into a staged workflow for dose selection, pathway readouts, and troubleshooting—while keeping model-specific results distinct from general recommendations.

• Ginsenoside Rg6 Sensitizes Cisplatin-Resistant EOC

  2026-09-24

  A 2025 study reports that ginsenoside Rg6 reduces fucosylation and promotes autophagy in cisplatin-resistant epithelial ovarian cancer cells, with changes linked to GRB2–ERK1/2–mTOR signaling. The findings support further investigation of Rg6 as a combination-treatment candidate, while leaving key questions about dose, selectivity, and clinical translation unresolved.

• Patient-Derived Gastric Cancer Assembloids

  2026-09-23

  Shapira-Netanelov and colleagues developed gastric cancer assembloids that combine patient-matched tumor organoids with tumor-derived stromal cell populations. The models showed stromal-associated changes in gene expression and drug sensitivity, illustrating why tumor-only cultures may miss features relevant to preclinical response testing.

• Epidermal Growth Factor in MYC–TNBC Assays

  2026-09-23

  Epidermal Growth Factor is more than a proliferation reagent: it can define how MYC-driven breast cancer assays distinguish EGFR-dependent growth from drug-induced cell death. This guide integrates recombinant human EGF handling with insights from a recent EphA2 synthetic-lethality study to improve mechanistic assay design.

7901 records 1/527 page Next 12345 下5页 Last page